$54.99
▲ +$1.39
(+2.59%)
Vol 792K
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$3.3B
ROE
-17.2%
Margin
-286.4%
D/E
0.00
Beta
3.09
52W
$17–$116
Wall Street Consensus
12 analysts · Apr 20264
Strong Buy
5
Buy
3
Hold
0
Sell
0
Strong Sell
75.0%
Buy Rating
Price Chart
Similar Stocks
IRON
Disc Medicine Inc
$3.0B
KOD
Kodiak Sciences Inc
$1.7B
IMNM
Immunome Inc
$2.4B
SRPT
Sarepta Therapeutics Inc
$2.3B
BCRX
BioCryst Pharmaceuticals Inc
$1.6B
RLAY
Relay Therapeutics Inc
$1.5B
MLYS
Mineralys Therapeutics Inc
$2.9B
SNDX
Syndax Pharmaceuticals Inc
$1.8B
DAWN
Day One Biopharmaceuticals Inc
$956.9M
ADMA
ADMA Biologics Inc
P/E 20.7
$4.3B
Earnings
Beat rate: 100.0%
Next Report
May 11, 2026
EPS Estimate: $-2.83
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-2.83 | — | — |
| Dec 2025 | $-2.76 | $-2.44 | +$0.32 |
| Sep 2025 | $-3.59 | $-2.46 | +$1.13 |
| Jun 2025 | $-3.64 | $-3.18 | +$0.46 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -18.0% | -18.0% | -18.0% | -18.0% | -17.2% | -17.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -320.7% | -329.9% | -329.9% | -329.9% | -286.4% | -286.4% |
| Gross Margin | 44.2% | 43.2% | 43.2% | 43.2% | 46.9% | 46.9% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 9.23 | 9.23 | 9.23 | 9.23 | 7.61 | 7.61 |
Key Ratios
ROA (TTM)
-14.6%
P/S (TTM)
23.53
P/B
0.2
EPS (TTM)
$-11.63
Rev Growth 3Y
+104.8%
52W High
$115.76
52W Low
$16.56
$16.56
52-Week Range
$115.76
How does GRAL compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
GRAL valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
23.5
▲
83%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
0.2
▼
90%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
GRAL profitability vs Biotechnology peers
ROE
-17.2%
▲
75%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-286.4%
▲
0%
above
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
46.9%
▼
40%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-14.6%
▲
69%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
GRAL financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
7.6
▲
71%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
3.1
▲
219%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
GRAL fundamentals radar
GRAL
Peer median
Industry
GRAL profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio